Clinical Trial Update: Identification of Clopidogrel CYP2C19 Metabolizer and Thienopyridine Treatment After an Acute Coronary Syndrome

View source ↗

Summary

The completed trial investigates CYP2C19 metabolizer status and its implications for clopidogrel (a thienopyridine) therapy after an acute coronary syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• CLOPIDOGREL (CLOPIDOGREL)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Acute Coronary Syndrome | Status: COMPLETED